The Relationship of Antipsychotic Medication Class and Adherence with Treatment Outcomes and Costs for Florida Medicaid Beneficiaries with Schizophrenia
Antipsychotic medication, Adherence, Medicaid, Cost-effectiveness
Digital Object Identifier (DOI)
While some studies show a significant advantage in adherence rates with use of atypical versus typical antipsychotic medication, others show no advantage or mixed results (Jones et al. (2006). Archives of General Psychiatry, 63, 1079–1087; Rosenheck, (2006). Archives of General Psychiatry, 63, 1074–1076). This study examined treatment outcomes and costs associated with adherence rates by antipsychotic medication class for adult Medicaid beneficiaries in Florida diagnosed with schizophrenia. Outcomes examined include arrests, involuntary commitments, and physical and behavioral healthcare costs. Study findings demonstrate that medication adherence for persons with schizophrenia may be as important to treatment costs and benefits as the class of medication used.
Was this content written or created while at USF?
Citation / Publisher Attribution
Administration and Policy in Mental Health and Mental Health Services Research, v. 34, issue 3, p. 307-314
Scholar Commons Citation
Becker, Marion A.; Young, M. Scott; Chitando, Ezra; and Diamond, Ronald, "The Relationship of Antipsychotic Medication Class and Adherence with Treatment Outcomes and Costs for Florida Medicaid Beneficiaries with Schizophrenia" (2007). Mental Health Law & Policy Faculty Publications. 889.